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Abstract
Background: Amyotrophic	lateral	sclerosis	(ALS)	is	a	neurodegenerative	disease	char-
acterized	by	the	degeneration	of	the	motor	neurons.	To	date,	126	genes	have	been	
implicated	in	ALS.	Therefore,	the	heterogenous	genetic	background	of	ALS	requires	
comprehensive genetic investigative approaches.
Methods: In	this	study,	DNA	from	28	Hungarian	ALS	patients	was	subjected	to	tar-
geted	 high-	throughput	 sequencing	 of	 the	 coding	 regions	 of	 three	 Mendelian	 ALS	
genes: FUS, SETX,	and	C9ORF72.
Results: A	novel	heterozygous	missense	mutation	(c.791A>G,	p.N264S)	of	the	SETX 
gene	was	identified	in	a	female	patient	presenting	an	atypical	ALS	phenotype,	includ-
ing adult onset and lower motor neuron impairment. No further mutations were de-
tected	in	the	other	Mendelian	ALS	genes	investigated.
Conclusion: Our study contributes to the understanding of the genetic and phenotypic 
diversity	of	motor	neuron	diseases	(MNDs).	Our	results	also	suggest	that	the	elucida-
tion	of	the	genetic	background	of	MNDs	requires	a	complex	approach,	including	the	
screening of both Mendelian and non- Mendelian genes.
K E Y W O R D S
ALS4,	motor	neuron	disease,	p.N264S	missense	mutation,	SETX	gene,	targeted	sequencing
1  | INTRODUCTION
Amyotrophic	 lateral	sclerosis	 (ALS;	ORPHA803),	also	known	as	“Lou	
Gehrig’s	disease”,	is	a	clinically	heterogeneous	group	of	neurodegen-
erative disorders characterized by the death of motor neurons in the 
brain,	brainstem,	and	spinal	cord	resulting	in	fatal	paralysis	(Morrison	&	
Harding,	1994).	Approximately,	90%	of	ALS	cases	are	sporadic	and	the	
remaining	10%	are	familial	(Valdmanis	&	Rouleau,	2008).	The	lifetime	
risk	for	developing	the	disease	is	approximately	1/400	(Johnston	et	al.,	
2006).	Due	 to	 the	 complex	 genetic	 background	 of	 the	 disease,	 the	
underlying disease- causing variant is rarely established for individual 
cases	(Kenna	et	al.,	2013).	To	date,	126	genes	have	been	implicated	in	
ALS	(Abel,	Powell,	Andersen,	&	Al-	Chalabi,	2012).
The most common mutants identified for the Mendelian forms are 
located in the superoxide dismutase 1 (SOD1)	gene,	which	accounts	 for	
approximately	5%	of	the	ALS	forms	(Andersen	et	al.,	2007).	Mutations	in	
the senataxin (SETX) gene have been identified at a lower frequency than 
in the SOD1	gene	 in	ALS. SETX encodes a helicase protein involved in 
DNA	repair	and	RNA	production.	Homozygous	or	compound	heterozy-
gous SETX mutations are associated with the development of autosomal 
recessive	ataxia	with	oculomotor	apraxia	 type	2	 (AOA2;	Anheim	et	al.,	
2009).	In	addition,	heterozygous	SETX mutations have been associated 
2 of 7  |     TRIPOLSZKI eT aL.
with	the	autosomal	dominant	 form	of	 juvenile-	onset	ALS	 (ALS4;	Chen	
et	al.,	2004).	The	fused in sarcoma (FUS) gene is also associated with the 
Mendelian	 forms	 of	ALS.	FUS encodes a nucleoprotein that functions 
in	 DNA	 and	 RNA	metabolism.	 The	 chromosome 9 open reading frame 
72 (C9ORF72) has also been identified as a disease- causing gene of 
Mendelian	ALS	forms	(Pearson	et	al.,	2011).	A	heterozygous	hexanucle-
otide	(GGGGCC)	repeat	expansion	located	between	the	noncoding	exons	
1a and 1b of C9ORF72	has	been	recently	identified	in	patients	with	FTD	
and/or	ALS	(DeJesus-	Hernandez	et	al.,	2011;	Renton	et	al.,	2011).
Considering	the	onset,	the	symptoms,	and	the	course	of	the	dis-
ease,	 our	 aim	was	 to	 establish	 the	 frequencies	 of	mutations	 in	 the	
coding regions of the SETX,	FUS,	 and	C9ORF72	 genes	 in	Hungarian	
patients	(n	=	28)	that	did	not	carry	mutations	in	the	SOD1 gene. The 
investigated patients were also negative for the C9ORF72	hexanucle-
otide	repeat	expansion.
2  | PATIENTS AND METHODS
2.1 | Investigated individuals
The	 investigated	 patients	 (n	=	28)	 participated	 in	 this	 study	 were	
recruited	 from	 the	 Department	 of	 Neurology,	 University	 of	 Szeged,	
Szeged,	Hungary.	 All	 patients	 fulfilled	 the	 revised	 El	 Escorial	 and	 the	
Awaji-	shima	criteria	for	ALS	(de	Carvalho	&	Swash,	2009;	Ludolph	et	al.,	
2015).	According	to	the	revised	El	Escorial	criteria,	the	lower	motor	neu-
ron	disease	(MND;	progressive	muscular	atrophy)	is	determined	as	one	
of	the	“restricted	phenotypes”	of	ALS;	therefore,	one	patient	with	only	
lower	motor	neuron	involvement	was	also	diagnosed	as	ALS.	All	patients	
and	age-	and	sex-	matched	healthy	controls	(n	=	50)	were	of	Hungarian	
ancestry.	The	investigation	was	approved	by	the	Internal	Ethical	Review	
Board	 of	 the	 University	 of	 Szeged.	 Written	 informed	 consent	 was	
obtained	 from	patients	 and	healthy	 controls,	 and	 the	 study	was	 con-
ducted	according	to	the	Principles	of	the	Declaration	of	Helsinki.
2.2 | Next- generation sequencing
Genomic	DNA	was	 isolated	from	blood	using	the	DNeasy	Blood	and	
Tissue	 kit	 (QIAGEN,	 Godollo,	 Hungary).	 Amplicons	 (n	=	56)	 were	
designed	 (range	 519–704	bp;	 mean:	 612	bp)	 to	 cover	 the	 coding	
regions and the flanking introns of the investigated FUS,	 SETX,	 and	
C9ORF72	 genes,	 and	 an	 amplicon	 library	was	 prepared	 according	 to	
the Amplicon Library Preparation Manual	for	the	Roche	Junior	454	next-	
generation	sequencing	system	 (Roche,	Budaörs,	Hungary).	Amplicons	
were	purified	with	 the	Agencourt	AMPure	XP	kit	 (Beckman	Coulter,	
Budapest,	Hungary),	quantified	with	the	Quant-	iT	PicoGreen	Assay	(Life	
Technologies,	Budapest,	Hungary),	diluted	 separately	 to	1	×	107 mol-
ecules/μl	and	pooled.	Emulsion	PCR	and	next-	generation	sequencing	
were	performed	according	to	the	manufacturers’	protocols	(Roche).
2.3 | Bioinformatic analysis
To	improve	the	efficiency	of	the	Roche	pipeline,	composed	of	the	
Roche	 454	 GS	 Reference	Mapper	 for	 mapping	 (on	 UCSC	 human	
reference	 genome	 hg19)	 and	 Amplicon	 Variant	 Analyzer	 (v2.5p1)	
for	 variant	 calling,	 an	 additional	 in-	house	 pipeline	 was	 used.	
Sequencing	 reads	 were	 aligned	 to	 the	 reference	 genome	 (UCSC	
hg19)	using	Roche	454	GS	Reference	Mapper	and	Amplicon	Variant	
Analyzer	(version	2.5p1).	BAM	files	were	converted	to	FASTQ	and	
realigned	 to	 hg19	 using	 Bowtie2	 V.2.2.6	 (Langmead	 &	 Salzberg,	
2012).	Samtools	V.0.1.19	and	Python	V.2.7.11	were	used	for	addi-
tional	file	handling.	Variant	calling	was	performed	combining	GATK	
Unified	 Genotyper	 (Genome	 Analysis	 Tool	 Kit	 v.3.4;	 McKenna	
et	al.,	2010)	and	Platypus	(v.0.8.1;	Rimmer	et	al.,	2014).	The	anno-
tation	and	the	prioritization	steps	were	executed	with	ANNOVAR	
(15.06.07;	Wang,	Li,	&	Hakonarson,	2010).	Finally,	the	target	region	
reads	 depth	 was	 controlled	 using	 BEDTools	 (v.2.25.0;	 Quinlan	
&	Hall,	 2010)	 and	 the	 alternative	 allele	 frequency	was	 computed	
using	pysamstats	(v.0.24.2;	https://github.com).	Candidate	variants	
were	filtered	according	to	read	depth,	allele	frequency,	and	preva-
lence	 in	 genomic	 variant	 databases	 such	 as	 ExAc	 (v.0.3),	 ClinVar,	
Kaviar	 (including	1,000	g-	phase3,	 dbSNP146;	Glusman,	Caballero,	
Mauldin,	Hood,	&	Roach,	2011;	Landrum	et	al.,	2016).	Variant	pri-
oritization	 tools	 (PolyPhen2,	 SIFT,	 LRT,	MutationTaster,	Mutation	
Assessor)	 were	 used	 to	 predict	 the	 functional	 impact	 and	 then	
focused	on	variants	with	predicted	deleterious	consequences	(non-
sense	 SNVs,	 frameshift	 indels,	 essential	 splice	 variants,	 and	 com-
plex	indels).	The	putative	effect	on	splicing	efficiency	was	predicted	
using	 the	Human	Splicing	Finder	 (Desmet	et	al.,	 2009).	The	align-
ments	were	visualized	with	IGV	V.2.0.34.	(Robinson	et	al.,	2011).	All	
the identified disease- causing candidate variants were confirmed by 
direct sequencing.
3  | RESULTS
Our	next-	generation	sequencing	approach	did	not	detect	mutations	in	
the investigated coding regions of the FUS and C9ORF72 genes.
We	identified	a	novel	heterozygous	missense	mutation	(c.791A>G,	
p.N264S)	of	the	SETX	gene	(Figure	1a)	in	a	Hungarian	female	patient.	
This	patient	presented	with	a	lower	MND	phenotype,	which	started	
with	an	unsteady	gait	at	the	age	of	65.	Electroneurography	revealed	
motor	axonal	loss	in	the	right	tibial	and	peroneal	nerves	with	spared	
sensory innervation. The electromyography indicated subacute 
and	chronic	signs	of	denervation	and	reinnervation.	One	year	 later,	
	follow	 up	 examinations	 indicated	 that	 denervation	 had	 spread	 to	
several	muscles	of	both	lower	extremities,	and	the	clinical	and	elec-
trophysiological signs of denervation appeared in the muscles of the 
upper	 extremities.	At	 the	 time	 blood	was	 obtained,	 the	 interosse-
ous	muscles	were	wasted,	dysarthria	and	dysphagia	had	developed	
with	 diminished	 gag	 reflex	 and	 lack	 of	 deep	 tendon	 reflexes	were	
observed all over the body. Muscle strength was generally 3/5 in the 
upper	extremities	and	2/5	 in	the	 lower	extremities.	Sensory	deficit	
was	 not	 observed	 and	 the	 extraocular	 muscles	were	 not	 involved	
in	 the	 disease	 process.	 The	 external	 sphincter	 muscles	 were	 also	
spared.	During	 the	3.5	year-	course	 of	 the	 disease,	 corticospinal	 or	
corticobulbar	 signs	 were	 not	 detected	 with	 physical	 examination	
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and with magnetic resonance images of the central nervous system. 
Progressive weakness was observed. Other diseases causing simi-
lar	 symptoms	were	 all	 excluded	 (thyroid	 and	 parathyroid	 diseases,	
paraneoplastic	 syndromes,	 gammopathies,	 multifocal	 motor	 neu-
ropathy	with	ganglioside	antibodies).	Ataxia	and	oculomotor	apraxia	
were	 not	 noted	 in	 the	 follow	 up	 examinations.	 The	 cerebrospinal	
fluid proved to be normal. The patient passed away at the age of 69 
and the cause of death was determined to be respiratory failure due 
to weakness of the respiratory muscles. No other members of the 
family were affected. The autopsy revealed a decreased number of 
motor	neurons	in	the	spinal	cord	and	diminished	number	of	axons	in	
the	ventral	roots.	Hyaline	inclusions	were	noted	in	the	remaining	spi-
nal	motor	neurons.	Histological	examination	of	the	striated	muscles	
(proximal	and	distal	 in	the	extremities,	 in	the	diaphragm	and	 in	the	
tongue)	revealed	signs	of	neurogenic	atrophy.	There	were	no	signs	of	
degeneration	in	the	corticospinal	tracts.	The	motor	cortex	remained	
intact,	 and	 other	 parts	 of	 the	 brain	 (temporal	 and	 parietal	 lobes,	
hippocampus,	cerebellum,	thalamus,	pons,	and	the	medulla)	seemed	
to	be	normal	except	some	cell	 loss	 in	the	nuclei	of	the	hypoglossal	
and	 facial	 nerve.	Together	with	 the	 clinical	 symptoms,	 the	 disease	
course and the autopsy findings confirmed the diagnosis of an atypi-
cal	ALS	form	with	lower	motor	neuron	involvement.
The	 novel	 c.791A>G,	 p.N264S	 SETX mutation identified in 
this	 study	 was	 confirmed	 with	 direct	 sequencing	 (Figure	1b).	 SIFT,	
Polyphen,	and	Mutation	Taster	analyses	determined	this	variant	as	a	
damaging,	disease-	causing	mutation.	The	mutation	was	absent	in	the	
patient’s clinically healthy 45- year- old son and in the age- and gender- 
matched healthy control individuals. The heterozygous p.N264S muta-
tion	affects	the	N-	terminal	region	of	the	SETX	protein	(Figure	1c)	and	
is	located	in	a	region	which	is	conserved	among	mammals	(Figure	1d).	
According	 to	 the	 results	 of	 the	 Human	 Splicing	 Finder	 online	 pre-
diction	 tool,	 the	c.791A>G	mutation	could	 result	 in	activation	of	an	
exonic	cryptic	donor	site,	creation	of	an	exonic	silencer	site	or	alter-
ation	of	an	exonic	enhancer	site.
F IGURE  1 A	novel	mutation	in	the	SETX	gene.	(a)	Next-	generation	sequencing	identified	the	novel	heterozygous	missense	SETX mutation. 
(b)	The	presence	of	the	mutation	was	confirmed	using	direct	sequencing.	(c)	The	mutation	is	located	within	the	N-	terminal	domain	of	the	encoded	
protein.	(d)	The	region	of	the	mutation	is	highly	conserved	in	mammals
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4  | DISCUSSION
In	 this	 study,	 we	 investigated	 three	 Mendelian	 disease	 genes	
(SETX, FUS,	 and	C9ORF72)	 in	28	Hungarian	sporadic	ALS	patients.	
We	 identified	 a	 novel,	 disease-	causing	 heterozygous	 missense	
mutation	 (p.N264S)	 in	 the	 SETX	 gene.	 To	 date,	 only	 17	 patho-
genic SETX		mutations	 (Figure	2)	 have	 been	 implicated	 in	 the	
development	of	 the	 autosomal	 dominant	 juvenile	 form,	ALS4.	The	
typical	phenotype,	 present	 in	 the	 majority	 of	 the	 ALS4	 patients,	
presents as a combination of lower and upper motor neuron impair-
ments	(Avemaria	 et	al.,	 2011;	 Hirano	 et	al.,	 2011;	 Saracchi	 et	al.,	
2014).
Originally,	 the	 spectrum	of	 adult	MNDs	 included	ALS	with	 the	
combined	degeneration	of	 upper	 (cortical)	 and	 lower	 (pontobulbar	
and	spinal)	motor	neurons,	primary	 lateral	sclerosis	 (PLS)	with	only	
upper motor neuron lesion and lower MND with the damage of 
pontobulbar	and/or	spinal	motor	neurons	 (Victor	&	Ropper,	2000).	
In	 a	 recent	 work,	 Finsterer	 and	 Burgunder	 (2014)	 suggested	 that	
ALS	 can	manifest	 clinically	 as	 a	 continuum	 ranging	 from	exclusive	
impairment	of	the	upper	motor	neurons	to	exclusive	impairment	of	
the	lower	motor	neurons.	Exclusive	impairment	of	the	upper	motor	
neurons	can	manifest	in	PLS	characterized	by	spastic	paresis	of	the	
striated	muscles	without	 atrophy	and	denervation,	 increased	deep	
tendon	 reflexes,	 pathological	 reflexes	 designating	 upper	 motor	
neuron	 lesion	 (Finsterer	&	Burgunder,	2014).	Exclusive	 impairment	
of the lower motor neurons can contribute to the development of 
lower MNDs observed as atrophy of the striated muscles of the body 
due to degeneration of lower motor neurons with increasing weak-
ness,	decreased	muscle	tone,	electrophysiological	signs	of	denerva-
tion	 (fasciculations,	 fibrillations),	 lack	 of	 the	 deep	 tendon	 reflexes	
and,	 finally,	 inevitable	 death	 from	 respiratory	 failure	 (Finsterer	 &	
Burgunder,	2014;	Victor	&	Ropper,	2000).
The	 identified	novel	p.N264S	SETX	mutation	 is	associated	with	
an	 unusual	 ALS	 phenotype	 characterized	 by	 lower	 motor	 neuron	
impairment only. Our results further support the accepted view that 
ALS	 and	 lower	 MNDs	 are	 not	 different	 disease	 entities,	 but	 that,	
instead,	they	are	clinical	variants	of	the	same	disease	spectrum.	The	
phenotypic	 variation	 can	 be	 explained	 by	 yet	 unidentified	 genetic	
modifiers,	environmental	and/or	life	style	factors.	The	unusual	phe-
notype	observed	in	the	reported	Hungarian	patient	is	not	unique	in	
the literature of pathogenic heterozygous SETX	mutations.	A	similar	
atypical phenotype has been described in a Chinese patient carry-
ing	the	p.T1118I	heterozygous	missense	mutation	of	the	SETX gene 
(Zhao	et	al.,	2009).	Although	the	p.N264S	mutation	is	located	within	
the	N-	terminal	 region	 of	 the	 protein	 and	 the	 p.T1118I	mutation	 is	
located	in	a	region	of	yet	unknown	function,	both	of	these	mutations	
result	 in	 the	 development	 of	 the	 same	 unusual	 ALS4	 phenotype.	
Further	 studies	 are	 needed	 to	 elucidate	 the	underlying	mechanism	
responsible for the observed unusual phenotypes associated with the 
heterozygous	p.N264S	and	p.T1118I	missense	mutations	of	the	SETX 
gene	(Table	1).
The 17 known heterozygous missense mutations of the SETX 
gene	are	 located	 in	exons	1,	5,	8,	11,	12,	13,	17,	and	24	 (Table	2).	
Four	 of	 the	 17	 mutations	 are	 located	 within	 the	 helicase	 domain	
of	 the	SETX	protein	 (Chen	et	al.,	 2004;	Hirano	et	al.,	 2011;	Kenna	
et	al.,	 2013;	 Saracchi	 et	al.,	 2014).	 In	AOA2,	 homozygous	 or	 com-
pound heterozygous missense mutations located within the helicase 
domain are generally associated with less severe phenotypes than 
the	mutations	affecting	other	regions	of	the	protein	 (Anheim	et	al.,	
2009;	Moreira	 et	al.,	 2004).	A	 similar	 genotype–phenotype	 associ-
ation has not been observed for the heterozygous missense muta-
tions	associated	with	ALS4.	However,	 in	ALS4,	mutations	 impairing	
the region of the helicase domain are associated with cortical and 
spinal	motor	neuron	impairment,	whereas	others	located	outside	of	
F IGURE  2 SETX	mutations	associated	with	ALS4.	All	identified	disease-	causing	SETX	mutations	implicated	in	ALS4	are	heterozygous	
missense.	Other	types	of	mutations	have	not	been	detected	in	ALS4.	The	identified	mutations	are	located	in	coding	regions	and	distributed	
nearly evenly on the encoded protein. Mutation hot spots have not been detected. Mutations are located both within the N- terminal and 
helicase	domains	and	located	outside	these	regions,	suggesting	that	these	regions	have	as	yet	unidentified	pivotal	biological	functions
TABLE  1 Clinical	features	of	the	atypical	ALS4	phenotype
SETX mutation
Amino acid 
substitution Ethnic origin
Age of 
onset
Lower motor 
neuron sign
Upper motor 
neuron sign Bulbar sign
Sensory 
impairment Reference
c.791A>G p.N264S Hungarian 65 Present Absent Present Absent This study
c.3353C>T p.T1118I Chinese	(Han) 42 Present Absent Present Absent Zhao	et	al.	(2009)
     |  5 of 7TRIPOLSZKI eT aL.
this region can lead to the development of either spinal or bulbar 
motor	neuron	involvement	(Table	2).
It	has	also	been	demonstrated	that,	in	AOA2,	missense	mutations	
affecting	the	N-	terminal	or	the	helicase	domain	of	SETX	cause	phe-
notypes	similar	to	those	caused	by	deletions,	nonsense,	or	frameshift	
mutations	(Chen	et	al.,	2006).	However,	only	missense	SETX mutations 
have	been	implicated	in	the	development	of	ALS4,	to	date	(Avemaria	
et	al.,	 2011;	 Hirano	 et	al.,	 2011;	 Kenna	 et	al.,	 2013;	 Saracchi	 et	al.,	
2014);	 deletions,	 nonsense,	 frameshift,	 or	 other	 types	 of	mutations	
have	not	yet	been	detected	for	this	disease	(Table	2).
Our study further widens the geographic range for the origin of 
disease- causing heterozygous missense mutations of the SETX	gene,	
which	have	already	been	implicated	in	ALS	in	patients	from	different	
countries	 (Avemaria	 et	al.,	 2011;	 Hirano	 et	al.,	 2011;	 Kenna	 et	al.,	
2013;	Saracchi	et	al.,	2014).	To	the	best	of	our	knowledge,	our	study	
is the first demonstrating a novel SETX	mutation	in	the	Hungarian	ALS	
population	(Table	2).
In	 this	 study,	 we	 did	 not	 identify	 any	 mutations	 in	 the	 cod-
ing regions of the C9ORF72 gene. These results correlate well with 
the data reported in the literature; there are currently no reports of 
disease- causing mutation in the coding regions of the C9ORF72 gene 
(Kenna	et	al.,	2013;	Koppers	et	al.,	2013).
No mutations in FUS,	 another	Mendelian	gene	associated	with	
ALS,	were	detected	in	the	Hungarian	patients.	FUS mutations have 
been detected in two regions of the gene that consequently affect 
the	 encoded	 protein:	 approximately	 one-	third	 are	 located	 within	
exon	3	and	6	and	impair	the	glutamine-	glycine-	serine-	tyrosine-	rich	
and the arginine- glycine- glycine- rich domains of the protein. Two- 
thirds	of	the	mutations	are	located	within	the	region	including	exons	
12–15,	which	encodes	a	zinc	finger	and	arginine-	glycine-	glycine-	rich	
TABLE  2 Clinical manifestations of SETX	mutations	in	ALS4
SETX mutation
Amino acid 
substitution Affected exon
Impaired region of the 
protein Age of onset Affected sites Reference
c.8C>T p.T3I 1 N- terminal domain 8 Spinal Chen et al. 
(2004)
c.791A>G p.N264S 5 N- terminal domain 65 Both This study
c.814C>G p.H272D 5 N- terminal domain 66 Bulbar Kenna et al. 
(2013)
c.1166T>C p.L389S 8 N- terminal domain 17 Spinal Chen et al. 
(2004)
24 Spinal Avemaria	et	al.	
(2011)
c.2755G>C p.V919L 8 Unknown	function 68 Both Kenna et al. 
(2013)
rc.2842C>A p.P948T 8 Unknown	function 58 Bulbar Kenna et al. 
(2013)
c.2975A>G p.K992R 8 Unknown	function 78 Bulbar Kenna et al. 
(2013)
c.3353C>T p.T1118I 8 Unknown	function 42 Both Zhao	et	al.	
(2009)
c.4660T>G p.C1554G 8 Unknown	function 6 Spinal Hirano	et	al.	
(2011)
c.5587A>G p.T1863A 11 Unknown	function 61 Other Kenna et al. 
(2013)
c.5842A>G p.M1948V 12 Helicase	domain 47 Spinal Kenna et al. 
(2013)
c.6052A>G p.K2018E 13 Helicase	domain 54 Spinal Saracchi et al. 
(2014)
c.6085C>G p.K2029E 13 Helicase	domain 35 Spinal Hirano	et	al.	
(2011)
c.6407G>A p.R2136H 17 Helicase	Domain 6 Spinal Chen et al. 
(2004)
c.7640T>C p.I2547T 24 Unknown	function 30 Spinal Hirano	et	al.	
(2011)
c.7645G>A p.V2549I 24 Unknown	function 64 Spinal Kenna et al. 
(2013)
c.7682C>T p.S2561L 24 Unknown	function 84 Spinal Kenna et al. 
(2013)
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domains	 (Shang	 &	 Huang,	 2016).	 On	 the	 basis	 of	 our	 results,	 we	
hypothesize that FUS	 mutations	 in	 the	 Hungarian	ALS	 population	
might	be	very	rare.	This	hypothesis	is	supported	by	the	literature,	as	
FUS mutations have been reported to contribute to the development 
of	 the	disease	 in	approximately	0.5%	of	 the	patients	 (Kenna	et	al.,	
2013).
On	 the	 basis	 of	 our	 results	 and	 the	 results	 of	 previous	 studies,	
we	also	emphasize	that	the	genetic	screening	of	the	Mendelian	ALS-	
associated genes might not elucidate the causative genetic variant in 
the	majority	of	ALS	cases	(Cirulli	et	al.,	2015;	Kenna	et	al.,	2013).	The	
genetic	 heterogeneity	 of	ALS	 is	 extremely	 complex:	 rare	mutations	
of Mendelian genes and common variants of non- Mendelian genes 
can	 also	 contribute	 to	 the	 development	 of	 the	 disease	 (Abel	 et	al.,	
2012).	Our	comprehensive	study	adds	novel	data	to	the	genetic	and	
	phenotypic	diversity	of	ALS	and	 indicates	 that	complex	approaches,	
high-	throughput	 methods,	 and	 large-	scale	 studies	 are	 needed	 to	
understand of the genetic heterogeneity of this disease.
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